Outset Medical (Nasdaq: OM) shares got a boost today on fourth-quarter results that topped the consensus forecast on Wall ...
Outset Medical is prominently recognized for its innovative Tablo Hemodialysis System, which revolutionized the dialysis ...
The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological ...
Outset Medical (Nasdaq: OM) announced today that the FDA says it addressed all issues cited in a 2023 warning letter.
Outset provided 2025 revenue guidance of $115 million to $125 million, and non-GAAP gross margin guidance in the high-30% range. Additionally, the company expects to use less than $50 million of cash ...
Q4 2024 Earnings Call Transcript February 19, 2025 Outset Medical, Inc. beats earnings expectations. Reported EPS is $-0.37, ...
The Tablo® Hemodialysis System, FDA cleared for use from the hospital to the home, represents a significant technological advancement that transforms the dialysis experience for patients and ...
The FDA clearance of the Tablo® Hemodialysis System as a solution for both hospital and home use signifies a significant advancement in dialysis technology, potentially expanding their customer base.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results